Press Release
18 November 2026 18:25:00 CET

Newbury Pharmaceuticals extends and increases loan agreement to SEK 40m, with right to early repayment

Newbury Pharmaceuticals AB has agreed with AB Slädens Pensionsstiftelse nr 3 to increase the existing loan by SEK 10 million to SEK 40 million and to extend its maturity to 30 June 2028. The amendment also gives Newbury the right to repay the loan early without a prepayment fee. The amendment is subject to approval by the Annual General Meeting on 20 January 2027.

Following approval, the total principal under the loan agreement will be SEK 40 million. The maturity date is extended by 12 months, from 30 June 2027 to 30 June 2028. The interest rate is unchanged at 11% per annum, payable at the end of each quarter. The additional SEK 10 million will be disbursed after approval by the Annual General Meeting. Until then, the existing loan of SEK 30 million continues on its current terms.

The amended agreement gives Newbury the right to repay the loan, in whole or in part, on 30 days' notice and without any prepayment fee. Newbury intends to refinance parts of the loan with bank financing over time.

In addition, the lender has expressed a non-binding intention to take SEK 10–15 million of the loan as shares instead of cash repayment if Newbury carries out a share issue. The conversion would be made by set-off, on the same terms as for other investors, and would reduce the company's debt and interest costs. No decision on a share issue has been made, and a conversion would require the approvals applicable at that time.

> *"This amendment secures the terms of this loan until mid-2028, while the right to early repayment and the lender's intention to convert part of the loan into equity give us flexibility to reduce our debt over time,"* says Karl Karlsson, CEO of Newbury Pharmaceuticals.

The lender, AB Slädens Pensionsstiftelse nr 3, is represented by Johan Orvelin, who is also a member of the Board of Directors of Newbury Pharmaceuticals AB. The transaction has therefore been treated as a related-party transaction. The Board of Directors, with Johan Orvelin recused, has unanimously approved the amendment and concluded that it is on arm's-length terms and in the best interests of the company and its shareholders. In accordance with good practice on the Swedish stock market, the amendment will be submitted to the Annual General Meeting on 20 January 2027 for approval. The Board's report on the transaction will be made available ahead of the meeting. No financial advisor has been used, and therefore no transaction costs apply.

Press Release
18 November 2026 18:25:00 CET

For more information, contact:

Karl Karlsson, CEO
karl.karlsson@newburypharma.com
Mobile: +46 46 12 11 20

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

This information is information that Newbury Pharmaceuticals is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-18 18:25 CET.

Attachments

Newbury Pharmaceuticals extends and increases loan agreement to SEK 40m, with right to early repayment